Niagen Bioscience, Inc. (NAGE)
Official siteCONSUMER DEFENSIVE • BIOTECHNOLOGY • NASDAQ
Market Cap: $163.54M
Last updated: Nov 17, 2026 at 11:03 AM ET
Niagen Bioscience, Inc. (NAGE) Stock Forecast
Analysts expect Niagen Bioscience (NAGE) to earn $0.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $118.41M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.08.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates rise 15.8%.
- Fiscal year ending Dec 31, 2026
- $0.02
- EPS consensus, revenue $118.41M
- Fiscal year ending Dec 31, 2027
- -$0.08
- EPS consensus, revenue $137.10M
- Next report
- Mar 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.02 | $0.02 to $0.02 | 1 | $118.41M | $117.90M to $118.83M | 5 |
| Dec 31, 2027 | -$0.08 | -$0.08 to -$0.08 | 1 | $137.10M | $127.10M to $145.00M | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.01 for the quarter ending Dec 31, 2026 to -$0.02 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.01 | -$0.05 to $0.02 | 8 | $30.52M | $28.91M to $31.90M | 8 |
| Mar 31, 2027 | -$0.02 | -$0.02 to -$0.02 | 1 | $31.49M | $29.20M to $33.45M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 77.8% from $0.09.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.02 | N/A | $0.09 | $0.09 | $0.09 | -77.8% |
| Fiscal year ending Dec 31, 2027 | -$0.08 | -$0.06 | $0.10 | $0.10 | $0.10 | N/A |
| Quarter ending Mar 31, 2027 | -$0.02 | N/A | $0.02 | $0.02 | $0.02 | N/A |
Frequently Asked Questions About NAGE
What is the NAGE stock forecast?
Consensus analyst estimates put Niagen Bioscience's EPS at $0.02 for the fiscal year ending Dec 31, 2026, on revenue of $118.41M. The consensus rating from 6 analysts is Buy.
How do analysts rate NAGE stock?
Of 6 analysts covering Niagen Bioscience, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NAGE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.02, with estimates from $0.02 to $0.02 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.08, with estimates from -$0.08 to -$0.08 from 1 analyst.
What revenue do analysts expect from Niagen Bioscience next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $118.41M, with estimates from $117.90M to $118.83M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $137.10M, with estimates from $127.10M to $145.00M.
How many analysts cover NAGE?
6 analysts rate Niagen Bioscience stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
NAGE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors